Korea University · Medicine
Professor Min Seo Kim's research lab focuses on clinical pharmacology and translational medicine, with a strong emphasis on evaluating the safety and efficacy of pharmacological interventions in infectious diseases such as COVID-19. The lab investigates the interplay between genetic predisposition and modifiable lifestyle factors in chronic disease risk, particularly obesity and its comorbidities. Additionally, the lab explores surgical innovation, particularly the learning curve and technical challenges associated with robotic surgery. Their work integrates large-scale biobank data with real-world evidence to inform clinical decision-making and public health policy.
Figures are computed from collected data and may differ slightly.
In this NMA, we found that anti-inflammatory agents (corticosteroids, tocilizumab, anakinra, and IVIG), convalescent plasma, and remdesivir were associated with improved outcomes of hospitalized COVID-19 patients. Hydroxychloroquine did not provide clinical benefits while posing cardiac safety risks when combined with azithromycin, especially in the vulnerable population. Only 29% of current evidence on pharmacological management of COVID-19 is supported by moderate or high certainty and can be
Bill & Melinda Gates Foundation.
This is the first study suggesting that technical immaturity substantially affects the surgical outcomes of robotic gastrectomy and that robotic gastrectomy is a complex procedure with a significant learning curve that has implications for physician training and credentialing.
The extent to which modifiable lifestyle factors offset the determined genetic risk of obesity and obesity-related morbidities remains unknown. We explored how the interaction between genetic and lifestyle factors influences the risk of obesity and obesity-related morbidities. The polygenic score for body mass index was calculated to quantify inherited susceptibility to obesity in 338,645 UK Biobank European participants, and a composite lifestyle score was derived from five obesogenic factors (
Two messenger RNA (mRNA) vaccines developed by Pfizer-BioNTech and Moderna are being rolled out. Despite the high volume of emerging evidence regarding adverse events (AEs) associated with the COVID-19 mRNA vaccines, previous studies have thus far been largely based on the comparison between vaccinated and unvaccinated control, possibly highlighting the AE risks with COVID-19 mRNA vaccination. Comparing the safety profile of mRNA vaccinated individuals with otherwise vaccinated individuals would
Open papers in the app to read, cite, and organize with AI.
